• Gallein: Advanced Modulation of G Protein βγ in Disease Mode

  2026-08-03

  Explore how Gallein, a selective G protein βγ subunit inhibitor, enables unprecedented precision in dissecting GPCR signaling pathways. This article reveals new insights and experimental strategies for cancer, immunology, and cardiometabolic research.

• CBD Attenuates Orofacial Inflammatory Pain via Multi-Domain

  2026-08-03

  This study demonstrates that cannabidiol (CBD) robustly alleviates both sensory and affective components of orofacial inflammatory pain in murine models. By mapping peripheral and central molecular mechanisms—including modulation of endocannabinoid, inflammatory, and serotonergic pathways—the research highlights CBD's translational potential for managing complex pain syndromes with emotional comorbidities.

• Syringin Enhances Sunitinib Sensitivity in RCC via EGFR/PI3K

  2026-08-02

  This study identifies syringin—a natural compound from Acanthopanax senticosus—as a promising therapeutic agent for renal cell carcinoma (RCC). By targeting the EGFR/PI3K/Akt pathway, syringin not only inhibits RCC cell proliferation and migration but also enhances the efficacy of sunitinib, providing a mechanistic strategy to counteract drug resistance.

• Lymphodepleting Chemotherapy Enhances Neoantigen T Cell Ther

  2026-08-01

  Sagie et al. demonstrate that lymphodepleting chemotherapy, by increasing immunoproteasome activity and HLA-I expression, significantly improves neoantigen presentation and the efficacy of T cell-based immunotherapies. Their findings provide mechanistic insight into how optimized chemotherapy regimens can synergize with adoptive cell therapy to overcome antigen presentation barriers in solid tumors.

• (S)-Mephenytoin: Redefining CYP2C19 Research With hiPSC Orga

  2026-07-31

  This thought-leadership article explores the mechanistic, experimental, and strategic considerations for translational researchers leveraging (S)-Mephenytoin as a benchmark CYP2C19 substrate in cutting-edge hiPSC-derived intestinal organoid models. The discussion spans current limitations of legacy systems, the transformative potential of organoid-based workflows, critical protocol parameters, and how APExBIO's (S)-Mephenytoin uniquely empowers precision pharmacokinetic research.

• Estradiol, ER Stress, and GPR30: Insights in Post-Shock Immu

  2026-07-31

  The referenced study elucidates how 17β-estradiol restores splenic CD4+ T lymphocyte function after hemorrhagic shock by inhibiting endoplasmic reticulum stress (ERS), mediated through ERα and GPR30 pathways. These findings refine mechanistic understanding of estrogen's rapid, non-genomic immune effects and suggest targeted tools for dissecting estrogen receptor signaling in trauma models.

• Angiotensin 1/2 (5-7): Protocols and Innovations for RAS & V

  2026-07-30

  Harness Angiotensin 1/2 (5-7) for both renin-angiotensin system and viral spike protein research with confidence. This article delivers protocol-driven insights, troubleshooting tactics, and new cross-domain findings that set your experiments ahead of the curve.

• SLC1A4 Drives Hepatocellular Carcinoma Progression via AKT A

  2026-07-30

  The reference study uncovers the oncogenic role of SLC1A4 in hepatocellular carcinoma (HCC) by demonstrating its activation of AKT signaling, leading to enhanced tumor cell proliferation, migration, and stemness. These findings highlight SLC1A4 as a promising diagnostic biomarker and therapeutic target for HCC and provide mechanistic insight into its functional relevance in liver cancer biology.

• (S)-(+)-Dimethindene maleate for M2 Receptor Antagonist Work

  2026-07-29

  (S)-(+)-Dimethindene maleate enables targeted blockade of the M2 muscarinic acetylcholine receptor and histamine H1 receptor in autonomic regulation, cardiovascular, and respiratory system research. It is not suitable for non-selective muscarinic assays or any diagnostic or therapeutic use. Precise adherence to solubility and handling best practices is essential for reproducible results.

• Go 6983: Pan-PKC Inhibitor Workflows for Advanced PKC Resear

  2026-07-29

  Go 6983 stands out as a pan-PKC inhibitor enabling precision dissection of PKC signaling in studies ranging from cancer progression to neurodevelopmental disorders. This guide translates recent mechanistic insights—including those from autism research—into actionable protocols, troubleshooting tips, and next-generation applications for PKC-dependent assays.

• HyperScribe T7 High Yield RNA Synthesis Kit Plus in mRNA Res

  2026-07-28

  The HyperScribe T7 High Yield RNA Synthesis Kit Plus enables precise, high-yield in vitro transcription workflows for advanced mRNA applications, including rare disease intervention. Its robust formulation and built-in troubleshooting make it a top-tier choice for researchers tackling RNA vaccine synthesis, antisense RNA production, and mRNA-based protein rescue.

• Lambda Protein Phosphatase (RNase-free): Redefining Function

  2026-07-28

  Explore how Lambda Protein Phosphatase (RNase-free) transforms functional proteomics by enabling precise analysis of phosphorylation dynamics. This article delves into its unique biochemical properties and strategic applications for advanced study of protein phosphorylation.

• Letrozole in Translational Research: Mechanistic and Strateg

  2026-07-27

  This thought-leadership article unpacks the mechanistic depth and translational potential of Letrozole, a potent non-steroidal aromatase inhibitor, with a focus on its use in breast cancer research and beyond. Bridging biochemical rationale, experimental practice, and strategic positioning, the content provides actionable guidance for translational researchers while addressing competitive landscapes and future outlooks. Supported by recent literature and contextual references, it highlights Letrozole’s unique molecular features, experimental advantages, and implications for personalized medicine.

• WIP1 Regulation of p38 MAPK Attenuates Pyroptosis in Sepsis-

  2026-07-27

  This study elucidates the role of WIP1 phosphatase in modulating p38 MAPK-dependent pyroptosis during sepsis-associated acute kidney injury (AKI). By integrating in vivo, in vitro, and single-cell transcriptomic approaches, the research demonstrates that WIP1 suppresses renal tubular cell pyroptosis via the p38 MAPK pathway, providing mechanistic insight with translational potential for metabolic and inflammatory research.

• Bazedoxifene as a Dual-Action SERM and IL-6/GP130 Pathway In

  2026-07-26

  This review synthesizes evidence on Bazedoxifene's capacity to inhibit the IL-6/GP130 signaling pathway—a mechanism implicated in cancer progression—alongside its established role as a third-generation selective estrogen receptor modulator (SERM) for postmenopausal osteoporosis. The findings highlight Bazedoxifene's potential for drug repurposing in oncology, underscoring the importance of pathway-selective pharmacology for future translational research.

449 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page